Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Oncology|February 28, 2009
Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature reviewBrian H Kim, Thomas Bradley, Julia Tai, et al.Anti-Cancer Drugs|July 3, 2008
In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemiaAnthony Calabro, Julia Tai, Steven L Allen, et al.Biochimica Et Biophysica Acta|May 15, 2002
WTH3, a new member of the Rab6 gene family, and multidrug resistanceJidong Shan, Liming Yuan, Daniel R Budman, et al.Molecular Medicine (Cambridge, Mass.)|March 23, 2011
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethalityMary Leung, David Rosen, Scott Fields, et al.Anti-Cancer Drugs|August 31, 2006
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysisDaniel R Budman, Richie Soong, Anthony Calabro, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 4, 2008
Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcomeMyra F Barginear, Martin Lesser, Meredith Lukin Akerman, et al.Leukemia Research|September 15, 2009
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.Cancer Investigation|May 29, 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabineSamit Hirawat, Jonathan Kolitz, Stuart M Lichtman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumorsGary K Schwartz, Aaron Weitzman, Eileen O'Reilly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869Anthony J Guidi, Donald A Berry, Gloria Broadwater, et al.Pageof 4